Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ATTAMAGE-A1.: Phase I/II Study of Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity MAGE-A1-Specific T-Cell Receptor (TCR) Combined With Atezolizumab in Patients With Metastatic MAGE-A1 Expressing Cancer

Next Previous
X
Search
Trial Profile

ATTAMAGE-A1.: Phase I/II Study of Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity MAGE-A1-Specific T-Cell Receptor (TCR) Combined With Atezolizumab in Patients With Metastatic MAGE-A1 Expressing Cancer

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 05 Aug 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MAGE-A1-specific T cell receptor-transduced autologous T-cell therapy-SignalOne Bio (Primary) ; Atezolizumab; Cyclophosphamide; Fludarabine; Programmed cell death 1 receptor antagonists
  • Indications Advanced breast cancer; Carcinoma; Male breast cancer; Non-small cell lung cancer; Triple negative breast cancer; Urogenital cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ATTAMAGE-A1

    • Most Recent Events

    • 09 Dec 2022 Status changed from suspended to discontinued.
    • 23 May 2022 Planned End Date changed from 1 Dec 2024 to 8 Apr 2023.
    • 23 May 2022 Planned primary completion date changed from 1 Dec 2024 to 8 Apr 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top